Evenity (Romosozumab) Side Effects: Rare But Serious Adverse Events

Why the "Rare But Serious" Category Demands Its Own Analysis

Most prescribing conversations about romosozumab focus on its impressive fracture reduction numbers. The FRAME trial (N=7,180) showed a 73% reduction in new vertebral fracture risk at 12 months versus placebo [1]. The ARCH trial (N=4,093) demonstrated superiority over alendronate for both vertebral and hip fracture prevention [2]. Those numbers are real.

What does not receive equal attention are the adverse events that appear infrequently but carry life-altering or fatal consequences when they do occur. For a drug given as 12 monthly injections to older postmenopausal women, many of whom already carry elevated baseline cardiovascular risk, getting the risk-benefit calculus right at the individual patient level depends on understanding the full adverse event profile.

This article focuses exclusively on rare but serious adverse events. Common, self-limiting reactions like injection-site pain (reported in approximately 17% of patients in FRAME [1]) are outside this scope.

Cardiovascular Events: The Boxed Warning

What the FDA Label Actually States

The FDA boxed warning added to Evenity in 2019 reads: "Romosozumab-aqqg may increase the risk of myocardial infarction, stroke, and cardiovascular death. Romosozumab-aqqg should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year." [3]

This is not a precaution or a warning. A boxed warning is the FDA's strongest safety communication, reserved for situations where the benefit-risk balance may be unfavorable in a defined population.

The ARCH Trial Signal

The cardiovascular signal emerged most clearly from the ARCH trial, which compared 12 months of romosozumab followed by alendronate against alendronate alone in 4,093 postmenopausal women with osteoporosis and prior vertebral fracture [2]. The trial was conducted in a population with meaningfully higher baseline cardiovascular risk than FRAME.

Serious cardiovascular adverse events occurred in 2.5% of romosozumab-treated patients versus 1.9% of alendronate-treated patients. Adjudicated major adverse cardiovascular events (MACE) were 50 events in the romosozumab arm versus 38 in the alendronate arm [2]. That absolute difference of 12 events across roughly 2,000 patients is modest, but statistically it crossed significance.

The FRAME trial, run in a population with lower cardiovascular risk, did not replicate the signal. Cardiovascular serious adverse events occurred in 2.3% of romosozumab versus 2.0% of placebo patients, a difference that did not reach statistical significance [1].

Biological Plausibility

Sclerostin is expressed in vascular smooth muscle and endothelium, not only in osteocytes. Preclinical data suggest sclerostin may exert a protective effect on vascular calcification [4]. Blocking sclerostin with romosozumab could therefore theoretically accelerate vascular calcification, particularly in patients with pre-existing atherosclerotic disease. This remains under investigation, but it provides a biologically coherent mechanism behind the ARCH signal.

Clinical Protocol: Who Should Not Receive Romosozumab

Per the FDA label [3] and the Endocrine Society Clinical Practice Guideline on osteoporosis pharmacotherapy [5], romosozumab should be avoided in patients who have experienced an MI or stroke within the preceding 12 months. For patients with known coronary artery disease, peripheral artery disease, or prior cerebrovascular events beyond the 12-month window, the decision requires an explicit risk-benefit discussion documented in the chart.

The American Association of Clinical Endocrinology (AACE) 2020 postmenopausal osteoporosis guidelines similarly flag cardiovascular history as a key patient-selection criterion before initiating romosozumab [6].

Osteonecrosis of the Jaw (ONJ)

Incidence and Background

Osteonecrosis of the jaw is an area of exposed, necrotic bone in the maxillofacial region that fails to heal over 8 weeks in a patient receiving or previously exposed to antiresorptive or angiogenesis-inhibiting therapy. It is most classically associated with bisphosphonates and denosumab, but the FDA label for Evenity includes ONJ as a labeled risk [3].

Across the romosozumab clinical trial program, approximately 0.05% of patients developed ONJ. That rate is consistent with what is seen with other antiresorptive agents in trial populations rather than real-world clinical practice, where invasive dental procedures and longer cumulative exposure push incidence higher.

A 2019 systematic review published in Osteoporosis International analyzing ONJ across bone-targeted therapies found that cumulative incidence in osteoporosis patients (as opposed to oncology patients on higher-dose regimens) ranges from 0.01% to 0.10% [7].

Risk Factors

The following factors increase ONJ probability:

• Prior or concurrent bisphosphonate or denosumab exposure
• Invasive dental procedures (extractions, implants, periapical surgery) during or after treatment
• Poor oral hygiene or active dental infection
• Corticosteroid use
• Smoking
• Diabetes mellitus with poor glycemic control

Prevention Protocol

The American Dental Association recommends completing all necessary invasive dental procedures before starting any antiresorptive therapy and deferring elective procedures during active treatment [8]. Before the first romosozumab injection, a dental exam with treatment of active infection and extraction of non-restorable teeth is standard practice.

Patients should be instructed to report jaw pain, swelling, loose teeth, or non-healing oral sores immediately. Romosozumab should be held if ONJ is diagnosed, though evidence on whether discontinuation accelerates healing is limited.

Atypical Femur Fractures (AFF)

Defining the Lesion

Atypical femur fractures occur in the subtrochanteric or femoral shaft region, often with prodromal thigh or groin pain. They are transverse or oblique (less than 30 degrees), non-comminuted, and occur with minimal or no trauma. The American Society for Bone and Mineral Research (ASBMR) published the current diagnostic criteria in 2014 [9].

AFFs were first described with long-term bisphosphonate use and subsequently with denosumab. Because romosozumab is designed to be followed by antiresorptive consolidation therapy, the cumulative AFF risk from a full treatment sequence (romosozumab plus subsequent alendronate or denosumab) may differ from either drug alone.

Trial Data

In the combined romosozumab clinical trial program totaling approximately 7,180 patient-years of exposure, 6 confirmed atypical femur fractures were identified [3]. All 6 occurred in patients in the romosozumab arm. The absolute number is small, but given that AFF under bisphosphonate monotherapy is estimated at 3.2 to 50 per 100,000 person-years depending on duration of use, the trial data do not clearly define the romosozumab-specific contribution [9].

Clinical Monitoring

Patients reporting new thigh, groin, or hip pain during romosozumab therapy should receive bilateral femur X-rays. If cortical thickening of the lateral femoral cortex or a lucent line ("dreaded black line") is seen, orthopedic consultation is warranted and romosozumab should be held pending evaluation.

Severe Hypocalcemia

Mechanism and Risk Population

Romosozumab is a bone-forming agent. It rapidly increases bone mineral apposition during the first several months of treatment, which can draw calcium from the extracellular compartment. Patients with pre-existing vitamin D deficiency, hypoparathyroidism, malabsorption syndromes, or severe renal impairment (estimated GFR <30 mL/min/1.73 m²) face the highest risk of clinically significant hypocalcemia [3].

The FDA label explicitly contraindicates romosozumab in patients with hypocalcemia at the time of initiation and requires correction of hypocalcemia before starting treatment [3].

What "Correct Before Starting" Means in Practice

A practical pre-treatment checklist before the first romosozumab injection includes:

1. Serum calcium (total and ionized if renal disease present): must be within normal limits
2. 25-hydroxyvitamin D level: target above 30 ng/mL (75 nmol/L) before first dose
3. Estimated GFR: use with caution if 30 to 59 mL/min/1.73 m²; avoid if <30 mL/min/1.73 m²
4. Parathyroid hormone: check if calcium is borderline low
5. Dietary calcium intake: supplement to reach 1,200 mg total daily intake from food plus supplement

Re-check serum calcium 2 to 4 weeks after the first injection in high-risk patients (renal impairment, history of hypoparathyroidism, malabsorption).

Clinical Trial Incidence

In the FRAME trial, hypocalcemia adverse events were numerically low because patients with vitamin D deficiency were excluded and all participants received 500 to 1,000 mg supplemental calcium plus 800 IU vitamin D daily [1]. Hypocalcemia rates in real-world practice, where these protections may not be uniformly applied, are likely higher than trial rates suggest.

A 2021 pharmacovigilance analysis of the FDA FAERS database identified hypocalcemia as a disproportionately reported event for sclerostin inhibitors, with a reporting odds ratio suggesting a class effect [10].

Hypersensitivity and Injection-Site Reactions

Spectrum of Reactions

Serious hypersensitivity reactions to romosozumab are rare. The FDA label includes reports of angioedema, urticaria, and erythema multiforme [3]. These are distinct from the common injection-site reactions (pain, redness, bruising) that affect roughly 17% of patients [1].

Angioedema and anaphylaxis require immediate discontinuation of romosozumab and standard emergency management: epinephrine 0.3 mg IM for anaphylaxis, antihistamines, corticosteroids as needed, and monitoring for biphasic reactions.

Timing

Most hypersensitivity reactions described in post-marketing reports occur within minutes to hours of injection, consistent with an IgE-mediated or mixed mechanism. Patients with a prior serious reaction to biologic agents should be monitored for at least 30 minutes after the first injection.

Post-Market Surveillance: What FAERS Adds

The FDA Adverse Event Reporting System (FAERS) provides real-world pharmacovigilance data that extend beyond the controlled trial environment. Post-approval FAERS reports for romosozumab have highlighted several signal clusters consistent with the labeled risks described above [11].

The Endocrine Society's 2022 updated guideline on osteoporosis management notes that post-market safety monitoring for romosozumab remains an active area, particularly regarding long-term cardiovascular outcomes in broader real-world populations than those enrolled in FRAME and ARCH [5].

"The cardiovascular signal from ARCH, while based on a higher-risk population, means clinicians should carefully evaluate each patient's cardiac history before prescribing romosozumab," states the 2020 AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis [6].

Rebound Bone Loss After Discontinuation

The Transition Problem

Romosozumab produces substantial gains in bone mineral density (BMD) during its 12-month treatment window. At the lumbar spine, FRAME reported a mean BMD increase of 13.3% at 12 months versus placebo [1]. However, upon discontinuation without antiresorptive follow-on therapy, rapid bone loss occurs.

This is not a direct toxic adverse event, but the clinical consequence of mismanaging the transition may be as harmful as a drug side effect: patients who stop romosozumab without initiating alendronate or denosumab can lose a large fraction of their BMD gains within 12 months [2].

The ARCH trial protocol, which transitioned patients from romosozumab to alendronate, maintained BMD gains through 24 months total [2]. Transition to antiresorptive therapy at month 12 is therefore not optional; it is a required component of the treatment strategy.

Implication for Sequential Therapy Risk

Because antiresorptive agents (especially bisphosphonates) carry their own ONJ and AFF risks, the total duration of antiresorptive exposure for a patient who receives romosozumab followed by alendronate is additive. Patients and prescribers should track cumulative antiresorptive exposure in years when evaluating ONJ and AFF risk over time.

Summary Risk Table

| Adverse Event | Approximate Incidence in Trials | FDA Label Status | Key Risk Factors | |---|---|---|---| | Major cardiovascular events (MI/stroke) | 2.5% vs 1.9% alendronate in ARCH [2] | Boxed Warning | Prior MI/stroke, atherosclerosis | | Osteonecrosis of the jaw | ~0.05% | Labeled Warning | Prior antiresorptive use, dental procedures | | Atypical femur fracture | 6 cases / 7,180 patient-years [3] | Labeled Warning | Long antiresorptive history | | Severe hypocalcemia | Low in trials (corrected patients); higher post-market | Contraindication if active | Vitamin D deficiency, renal impairment | | Serious hypersensitivity | Rare (<1%) | Labeled Warning | Prior biologic hypersensitivity |

Prescriber Decision Framework

Patient selection for romosozumab requires simultaneous screening across multiple risk domains. The following sequence is recommended before initiating therapy:

Step 1. Cardiovascular screening. Review cardiac history for MI, stroke, or unstable angina in the past 12 months. If present, romosozumab is contraindicated. If beyond 12 months, document explicit risk-benefit discussion.

Step 2. Dental evaluation. Refer to dentist for exam and treatment of active disease. Defer elective invasive procedures until after the 12-month course is completed.

Step 3. Biochemical readiness. Check serum calcium, 25-OH vitamin D, eGFR. Correct deficiencies before injection 1. Recheck calcium in high-risk patients at 2 to 4 weeks post-injection 1.

Step 4. Fracture symptom education. Counsel patients to report new thigh or groin pain immediately (AFF surveillance) and any jaw symptoms (ONJ surveillance).

Step 5. Transition plan. Document the antiresorptive agent planned for month 13 before starting romosozumab. Do not leave this decision to the end of treatment.